10-15 Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

10-15 Associates’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$246K	Hold	440	–	–	0.05%	86
2020 Q2	$274K	Hold	440	–	–	0.06%	85
2020 Q1	$215K	Buy	+440	New	+$181K	0.05%	86
2017 Q3	–	Sell	-465	Closed	-$228K	–	106
2017 Q2	$228K	Buy	+465	New	+$203K	0.06%	86
2016 Q1	–	Sell	-452	Closed	-$245K	–	118
2015 Q4	$245K	Buy	452 +2	+0.4%	+$1.08K	0.07%	106
2015 Q3	$209K	Hold	450	–	–	0.07%	100
2015 Q2	$229K	Buy	+450	New	+$220K	0.07%	110

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

10-15 Associates's REGN Position: Q3 2020 in Review

10-15 Associates held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2020 at 440 shares worth $246K. The position accounts for 0.05% of the portfolio, ranked #86.

10-15 Associates first reported a position in REGN in Q2 2015 and has held it in 7 quarters since. The position peaked at $274K in Q2 2020. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

10-15 Associates held 440 shares of Regeneron Pharmaceuticals worth $246K as of Q3 2020.
10-15 Associates left its Regeneron Pharmaceuticals share count unchanged in Q3 2020.
Regeneron Pharmaceuticals made up 0.05% of 10-15 Associates's portfolio in Q3 2020, its #86 holding.
10-15 Associates first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 7 quarters since.
10-15 Associates's Regeneron Pharmaceuticals position peaked at $274K in Q2 2020.
907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on 10-15 Associates's 13F filing for Q3 2020, filed 13 Oct 2020.